Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,216.00    38.00 (1.74%)
Bid:
2,220.00
Ask:
2,228.00
Spread: 8.00 (0.36%)
Market Cap: £1.47b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Board Appointment

7 May 2009 07:00

RNS Number : 8018R
Genus PLC
07 May 2009
 



For immediate release 7 May 2009

Genus plc

('Genus' or 'the Company')

Board Appointment

Genus, a leading global animal genetics company, is pleased to announce the appointment of Mike Buzzacott as a non-executive director.

Mike Buzzacott spent 34 years at BP prior to his retirement in 2004, holding a number of international roles including Finance & Control Director Asia Pacific, CFO BP Nutrition and Group Vice President Petrochemicals. He is currently a non-executive director and Audit Committee chairman of Rexam Plc (retiring in May 2009) and Croda Plc. He is also a non-executive director of Scapa Plc. He was Chairman of Biofuels Plc from 2006 until its re-registration in 2007 as a private company.

Mike Buzzacott will chair the Company's Audit Committee and will be a member of the Remuneration Committee.

Commenting on the appointment, John Hawkins, Chairman of Genus, said:

"We are delighted to welcome Mike to the Board. He brings with him considerable experience gained in overseas international markets that will greatly benefit Genus during its next stage of strategic development and beyond."

There are no further details to be disclosed in respect of Mike Buzzacott under paragraph 9.6.13R of the Listing Rules of the UK Financial Services Authority.

For further information please contact:

Genus plc Tel: 01256 345970

John Hawkins, Chairman

Richard Wood, Chief Executive

Buchanan Communications Tel: 0207 466 5000

Charles Ryland , Isabel Podda

About Genus

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. It's non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain. 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in BasingstokeEngland, Genus companies operate in 30 countries on six continents, with research laboratories located in MadisonUSA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOACKAKDPBKDDPK
Date   Source Headline
8th Mar 20221:13 pmRNSNotification of Major Holdings
24th Feb 20227:00 amRNSCollaboration between PIC and Olymel LP in Canada
24th Feb 20227:00 amRNSInterim Results
1st Feb 20224:57 pmRNSBlock listing Interim Review
4th Jan 20229:47 amRNSTotal Voting Rights
26th Nov 202110:18 amRNSDisclosure of Rights Attached to Equity Shares
24th Nov 20215:51 pmRNSDirector/PDMR Shareholding
24th Nov 20212:47 pmRNSResult of AGM
24th Nov 20212:30 pmRNSDirector/PDMR Shareholding
24th Nov 20217:00 amRNSAGM Trading Update
10th Nov 20212:28 pmRNSNotification of Major Holdings
15th Oct 20217:00 amRNSAnnual Report and Annual General Meeting
13th Oct 20215:56 pmRNSDirector/PDMR Shareholding
1st Oct 20213:58 pmRNSTotal Voting Rights
30th Sep 20219:59 amRNSDirector Declaration
29th Sep 20212:59 pmRNSNotification of Major Holdings
15th Sep 20214:45 pmRNSDirector/PDMR Shareholding
14th Sep 20214:32 pmRNSDirector/PDMR Shareholding
9th Sep 20217:00 amRNSPreliminary Results
1st Sep 20212:05 pmRNSTotal Voting Rights
2nd Aug 20214:00 pmRNSBlock listing Interim Review
2nd Aug 202110:09 amRNSTotal Voting Rights
1st Jul 20214:39 pmRNSTotal Voting Rights
28th Jun 20215:00 pmRNSPIC AND SERGAL ENTER INTO STRATEGIC RELATIONSHIP
22nd Jun 20217:00 amRNSCapital Markets Event & PRRSv Programme Update
14th Jun 20213:01 pmRNSNotification of Major Holdings
7th Jun 202110:42 amRNSApplication For Additional Listing
4th Jun 20214:38 pmRNSNotification of Major Holdings
17th May 20211:23 pmRNSNotification of Major Holdings
13th May 202110:50 amRNSDirector/PDMR Shareholding
9th Apr 20214:10 pmRNSDirector/PDMR Shareholding
6th Apr 20216:00 pmRNSDirector/PDMR Shareholding
1st Apr 20215:49 pmRNSTotal Voting Rights
31st Mar 20212:59 pmRNSDirector/PDMR Shareholding
22nd Mar 20217:00 amRNSBoard Changes
19th Mar 202112:20 pmRNSDirector/PDMR Shareholding
9th Mar 20215:41 pmRNSNotification of Major Holdings
3rd Mar 20215:19 pmRNSDirector/PDMR Shareholding
26th Feb 202112:39 pmRNSDirector/PDMR Shareholding
25th Feb 20217:00 amRNSInterim Results
1st Feb 202111:08 amRNSBlock listing Interim Review
1st Feb 202111:08 amRNSTotal Voting Rights
18th Jan 20217:00 amRNSTrading Update
2nd Dec 20205:44 pmRNSDirector/PDMR Shareholding
25th Nov 20201:13 pmRNSResult of AGM
25th Nov 20207:00 amRNSAGM Trading Update - Strong Performance Continues
11th Nov 20201:03 pmRNSNOTIFICATION OF MAJOR HOLDINGS
16th Oct 20208:00 amRNSAnnual Report and Annual General Meeting
1st Oct 20203:45 pmRNSTotal Voting Rights
25th Sep 20206:14 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.